Why insider trading matters?
What separates FormWhispers.com from others is that we created it to meet our own needs and we use it everyday to make better investment decisions. We will keep improving it to serve us better and to serve you better.
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. It primarily serves physicians and pharmacists through direct sales. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2017-10-30 | CHAWLA SAM | Director | Buy | 3,100,000 | $3.05 | $9,455,000 | No |
| 2017-10-26 | PERCEPTIVE ADVISORS LLC | 10%-Owner | Buy | 3,100,000 | $3.05 | $9,455,000 | No |
| 2017-08-21 | Diaz-Mitoma Francisco | Chief Medical Officer | Buy | 3,000 | $3.17 | $9,510 | No |
| 2017-08-21 | Baxter Jeff | CEO, President | Buy | 10,000 | $3.22 | $32,200 | No |
| 2017-08-10 | Baxter Jeff | CEO, President | Buy | 10,000 | $3.28 | $32,800 | No |
Insider Smart
Insider Smart